NASDAQ$TRAW
Traws Pharma Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Reported financial results for the second quarter of 2021 and provided a business update.
Onconova Therapeutics reported a net loss of $4.2 million, or $0.27 per share, for the second quarter of 2021. As of June 30, 2021, cash and cash equivalents were $43.7 million.
- Initiated U.S. Phase 1 study of ON 123300 and opened enrollment to the second cohort.
- Partner HanX Biopharmaceuticals is enrolling to the third dose cohort of the complementary Phase 1 study in China.
- Reported encouraging preliminary results from the investigator-initiated study evaluating rigosertib plus nivolumab in advanced KRAS-mutated NSCLC.
- Company believes that its cash and cash equivalents will be sufficient to fund ongoing clinical trials and business operations for more than eighteen months.
Headline financials
Revenue & EPS history
Onconova · Revenue · Quarterly
$57K
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q2 2021
-0.7%
Avg return
Earnings day
-2.6%
Avg return
5 days after
-5.0%
Avg return
30 days after
25%
9 / 36 earnings
Positive
+22.6%
Q3 2025
Best reaction
-22.6%
Q4 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +15.3% | — | — | |
| Q4 2026 | -22.6% | -12.6% | +18.2% | |
| Q3 2025 | +22.6% | +19.2% | +31.6% | |
| Q2 2025 | -1.2% | -18.3% | +16.5% | |
| Q1 2025 | -3.6% | +1.4% | +2.1% | |
| Q4 2024 | +6.0% | -1.0% | -30.5% | |
| Q3 2024 | -11.7% | -16.8% | -17.7% | |
| Q2 2024 | -2.7% | +5.4% | -5.4% | |
| Q1 2024 | -2.5% | -1.5% | -9.1% | |
| Q4 2023 | -1.5% | -19.8% | -34.7% | |
| Q3 2023 | -3.1% | +0.0% | +15.4% | |
| Q2 2023 | -2.0% | -11.2% | -20.4% | |
| Q1 2023 | -4.0% | -5.3% | +53.3% | |
| Q4 2022 | -3.9% | -5.3% | +51.3% | |
| Q3 2022 | +18.3% | +36.6% | +7.0% | |
| Q2 2022 | +3.9% | -1.6% | -10.1% | |
| Q1 2022 | -1.6% | -2.1% | -26.1% | |
| Q4 2021 | +10.0% | +13.7% | +0.6% | |
| Q3 2021 | +1.2% | -1.5% | -18.3% | |
| Q2 2021 | -4.4% | -11.8% | -1.2% | |
| Q1 2021 | -3.1% | -9.0% | -26.4% | |
| Q4 2020 | +0.0% | -3.6% | -97.0% | |
| Q3 2020 | +0.0% | +3.8% | +42.3% | |
| Q2 2020 | -3.6% | -6.4% | -79.1% | |
| Q1 2020 | +0.0% | +5.6% | +69.4% | |
| Q3 2019 | -7.1% | -16.7% | -35.7% | |
| Q2 2019 | -2.1% | -5.6% | +7.3% | |
| Q1 2019 | -6.3% | -11.5% | -15.9% | |
| Q3 2018 | -11.5% | -3.1% | -25.1% | |
| Q2 2018 | -9.1% | -6.8% | +11.4% | |
| Q1 2018 | -5.4% | -2.7% | +40.5% | |
| Q3 2017 | -2.1% | -16.8% | -22.1% | |
| Q2 2017 | -0.5% | -16.7% | -19.3% | |
| Q1 2017 | -0.5% | -0.5% | -9.0% | |
| Q3 2016 | +11.0% | +28.7% | -15.8% | |
| Q2 2016 | +2.5% | +4.2% | -21.9% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro